SequelSEC

MAIA Biotechnology, Inc. MAIA

Pharmaceutical Preparations · CIK 0001878313 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2024-12-31
Operating income
Unavailable
Fiscal year ended 2024-12-31
Free cash flow
Unavailable
Fiscal year ended 2024-12-31

Valuation, from the filing

Public float$48.95MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.81Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.65x36th

This page shows 5 annual periods of income statement, balance sheet and cash flow figures normalized from MAIA Biotechnology, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MAIA Biotechnology, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312022-09-302022-06-30
RevenueUnavailableUnavailable$0$0Unavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailable
Operating incomeUnavailableUnavailable-$4.20M-$5.10M-$3.44M
Net incomeUnavailableUnavailableUnavailableUnavailable-$3.31M
Research & developmentUnavailableUnavailable$2.39M$2.34M$2.12M
Weighted-average diluted sharesUnavailableUnavailableUnavailableshares 10.17Mshares 8.20M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable$0Unavailable
Diluted EPSUnavailableUnavailableUnavailable$-0.48$-0.40
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrativeUnavailableUnavailable$1.80M$1.65M$1.32M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

MAIA Biotechnology, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312022-09-302022-06-30
Cash & equivalents$0$0$0$0$0
Total assets$10.16M$7.57M$12.02M$14.78M$9.76M
Current assets$10.15M$7.56M$11.81M$14.78M$8.61M
Total liabilities$6.52M$7.09M$3.51M$2.67M$3.10M
Current liabilities$3.83M$4.94M$3.27M$2.46M$3.10M
Total equity incl. NCI$3.63M$477.51K$8.51M$12.11M$6.66M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailable$0
Accounts payable$1.51M$1.64M$1.17M$1.02M$1.04M

Cash flow

MAIA Biotechnology, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312022-09-302022-06-30
Operating cash flowUnavailableUnavailable-$2.95M-$4.32MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flowUnavailableUnavailable-$192.90K$10.26MUnavailable
Net change in cashUnavailableUnavailable-$3.11M$5.91MUnavailable
Stock-based compensationUnavailableUnavailable$488.89K$532.44KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

MAIA Biotechnology, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312022-09-302022-06-30
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.65x1.53x3.61x6.02x2.78x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MAIA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-11View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.